Recent research from Northwestern University is generating excitement in the medical community by suggesting that a commonly used menopause medication could have significant implications for breast cancer prevention. The study, which focused on women with ductal carcinoma in situ (DCIS)—a non-invasive form of breast cancer—found that Duavee, a drug previously approved to treat menopausal symptoms, significantly reduced breast tissue cell growth, a key indicator of cancer progression. The findings, published in a press release, have sparked discussions about the potential dual role of this medication in both alleviating menopausal symptoms and serving as a preventive measure against invasive breast cancer.
The study involved 141 post-menopausal women diagnosed with DCIS, who were divided into two groups: one received Duavee, while the other received a placebo. After a month of treatment, the women underwent breast surgery. The results indicated that Duavee slowed the proliferation of breast tissue cells in those with estrogen receptor-positive DCIS, suggesting a possible protective effect against the progression to invasive breast cancer. Dr. Swati Kulkarni, the lead investigator and professor at the Feinberg School of Medicine, highlighted that the most encouraging outcome was the drug’s potential to reduce cancer risk while also managing menopausal symptoms, such as hot flashes.
However, the study’s lead researcher emphasized that the findings are preliminary and have not yet been published in a peer-reviewed medical journal. She expressed enthusiasm about the potential of Duavee to serve as both a treatment for menopausal symptoms and a preventive measure, but cautioned that more research is needed before any definitive conclusions can be drawn. “What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer,” Kulkarni noted.
Experts like Dr. Sheheryar Kabraji, who was not involved in the study, acknowledged the study’s significance but reminded that such preliminary findings require further validation. Kabraji pointed out that the study focused on reducing levels of a specific protein and did not directly show a reduction in DCIS recurrence or the development of invasive cancer. He underscored the need for larger, long-term studies to determine the drug’s efficacy as a preventive treatment for breast cancer.
Despite the preliminary nature of the research, the potential benefits of Duavee for women with a high risk of breast cancer and menopausal symptoms are noteworthy. Women with high-risk lesions, who are typically advised against standard hormone therapies, may find this medication to be an alternative option. However, Dr. Kulkarni reiterated that the drug is not currently approved for breast cancer prevention and is intended for the treatment of menopausal symptoms. She encouraged further research to confirm these findings and explore the drug’s broader implications in breast cancer prevention.
The medical community remains cautious but hopeful about the prospect of Duavee as a potential treatment for both menopause-related symptoms and breast cancer prevention. As the research continues, more data will be essential to determine the drug’s true efficacy and its role in the broader landscape of breast cancer treatment and prevention strategies.